Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05095363 · ClinicalTrials.gov registry record · NA
Palliative Care Planner (PCplanner)
A NA study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT05095363: Completed NA study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by Duke University.
NCT05095363 is a NA study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease that has completed, run by Duke University. The registered enrollment target is 43 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05095363, a NA study of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine the feasibility, acceptability, and evidence for clinical impact of a mobile app-based program called Palliative Care Planner (PCplanner) in addressing needs and promoting advance care planning discussions among patients with idiopathic pulmonary fibrosis and their clinicians.
Primary Outcome
Number of participants who stated intervention was easy to use as measured by patient survey.
Conditions Studied
Interventions
- BEHAVIORAL PCplanner
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-03-16 |
| Est. Completion | 2023-03-31 |
| Phase | NA |
What the finished NCT05095363 record still lists
NCT05095363 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which PCplanner is the first listed.
NCT05095363 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05095363 about?
NCT05095363 is a clinical study titled "Palliative Care Planner (PCplanner)". The purpose of this research study is to determine the feasibility, acceptability, and evidence for clinical impact of a mobile app-based program called Palliative Care Planner (PCplanner) in addressing needs and promoting advance care planning discussions among patients with idiopathic pulmonary fi...
What is the current status of trial NCT05095363?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2022-03-16. Estimated completion is 2023-03-31.
What conditions does trial NCT05095363 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease.
What interventions are being tested in trial NCT05095363?
The interventions under investigation include: PCplanner (BEHAVIORAL).
Who is sponsoring clinical trial NCT05095363?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05095363 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05095363's enrollment target sits among peer trials
43 35th of 51 higher than 17 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis
ACTIVE NOT RECRUITING · NA
-
IPF mHealth Exercise Study
COMPLETED · NA
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI